Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05081024 · ClinicalTrials.gov registry record
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
A clinical trial of Rectal Adenocarcinoma and Stage III Rectal Cancer AJCC v8, sponsored by OHSU Knight Cancer Institute.
- Recruiting
- Registry status
- 50
- Enrollment target
- 2
- Study locations
NCT05081024 is a study of Rectal Adenocarcinoma and Stage III Rectal Cancer AJCC v8 that is actively recruiting participants, run by OHSU Knight Cancer Institute. The registered enrollment target is 50 participants, below the 122-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (59% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05081024, a study of Rectal Adenocarcinoma and Stage III Rectal Cancer AJCC v8, is actively recruiting participants, sponsored by OHSU Knight Cancer Institute.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study measures the levels of circulating tumor DNA (ctDNA) in patients with stage II-III rectal cancer before, during, and after treatment to find out if the presence or absence of ctDNA in patient's blood using the Signatera test can be used to gauge how different treatments may affect rectal cancer. ctDNA is DNA from the rectal cancer that is circulating in the blood. The purpose of this study is to understand if the way rectal tumors respond to standard treatment can be associated with varying levels of ctDNA.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Biopsy
- OTHER Electronic Health Record Review
Study Locations (2)
Oregon
- OHSU Knight Cancer Institute - Portland
Washington
- Fred Hutch - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-09-03 |
| Est. Completion | 2026-09-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05081024
The ClinicalTrials.gov registry entry for NCT05081024 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 122-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (59% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Rectal Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT05081024 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Oregon, Washington.
Frequently Asked Questions
What is clinical trial NCT05081024 about?
NCT05081024 is a clinical study titled "Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer". This study measures the levels of circulating tumor DNA (ctDNA) in patients with stage II-III rectal cancer before, during, and after treatment to find out if the presence or absence of ctDNA in patient's blood using the Signatera test can be used to gauge how different treatments may affect rectal ...
What is the current status of trial NCT05081024?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2021-09-03. Estimated completion is 2026-09-03.
What conditions does trial NCT05081024 study?
This clinical trial studies the following conditions: Rectal Adenocarcinoma, Stage III Rectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8.
What interventions are being tested in trial NCT05081024?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Biopsy (PROCEDURE), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT05081024?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05081024 being conducted?
This trial has 2 study locations across Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
RECRUITING · Phase 3
-
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
RECRUITING
-
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
RECRUITING · Phase 2
-
Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.